All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2022-10-18T08:32:20.000Z

Zanubrutinib exhibits PFS benefit in relapsed/refractory CLL/SLL: topline results from the ALPINE trial

Oct 18, 2022
Share:

Bookmark this article

Topline results obtained from final progression-free survival analysis (PFS) of the phase III ALPINE trial (NCT03734016) indicate that zanubrutinib is efficacious and well tolerated in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1

ALPINE is a global, randomized, phase III study of zanubrutinib versus ibrutinib in 652 patients with previously treated R/R CLL or SLL. The trial met all of its primary and secondary endpoints, with safety and final PFS analysis consistent with that of prior reports. This data adds weight to the growing body of evidence that zanubrutinib could provide a safe and effective treatment option for patients with R/R CLL and SLL.

  1. BeiGene announces positive topline results from final progression-free survival analysis of BRUKINSA® (zanubrutinib) compared to IMBRUVICA® (ibrutinib) in phase III chronic lymphocytic leukemia (CLL) trial. https://ir.beigene.com/news/beigene-announces-positive-topline-results-from-final-progression-free-survival-analysis-of-brukinsa-zanubrutinib-compared-to/a6b90281-b378-4051-afa3-3eaf04af0b5c/. Published Oct 13, 2022. Accessed Oct 13, 2022. 

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox